These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 27811556

  • 21. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [Abstract] [Full Text] [Related]

  • 22. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S.
    CNS Drugs; 2012 Oct 01; 26(10):883-92. PubMed ID: 22873680
    [Abstract] [Full Text] [Related]

  • 23. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.
    Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, Roy-Byrne P, Phillips K, Du Pont IJ.
    J Clin Psychopharmacol; 1999 Apr 01; 19(2):172-6. PubMed ID: 10211919
    [Abstract] [Full Text] [Related]

  • 24. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S.
    J Psychiatr Res; 2013 Feb 01; 47(2):175-80. PubMed ID: 23063327
    [Abstract] [Full Text] [Related]

  • 25. Cognitive-coping therapy for obsessive-compulsive disorder: a randomized controlled trial.
    Ma JD, Wang CH, Li HF, Zhang XL, Zhang YL, Hou YH, Liu XH, Hu XZ.
    J Psychiatr Res; 2013 Nov 01; 47(11):1785-90. PubMed ID: 23988179
    [Abstract] [Full Text] [Related]

  • 26. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.
    Yousefzadeh F, Sahebolzamani E, Sadri A, Mortezaei A, Aqamolaei A, Mortazavi SH, Shalbafan MR, Ghaffari S, Alikhani R, Mousavi SB, Naderi S, Shamabadi A, Jalilevand S, Akhondzadeh S.
    Int Clin Psychopharmacol; 2020 Sep 01; 35(5):254-262. PubMed ID: 32541380
    [Abstract] [Full Text] [Related]

  • 27. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
    Zheng H, Jia F, Guo G, Quan D, Li G, Huang H.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov 28; 43(11):1230-1235. PubMed ID: 30643068
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
    Farnia V, Gharehbaghi H, Alikhani M, Almasi A, Golshani S, Tatari F, Davarinejad O, Salemi S, Sadeghi Bahmani D, Holsboer-Trachsler E, Brand S.
    J Psychiatr Res; 2018 Sep 28; 104():137-143. PubMed ID: 30044966
    [Abstract] [Full Text] [Related]

  • 29. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D, de Geus F, van Megen HJ, Westenberg HG.
    J Clin Psychiatry; 2004 Aug 28; 65(8):1040-8. PubMed ID: 15323587
    [Abstract] [Full Text] [Related]

  • 30. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
    Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, Akhondzadeh S.
    Hum Psychopharmacol; 2017 Jul 28; 32(4):. PubMed ID: 28485008
    [Abstract] [Full Text] [Related]

  • 31. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.
    Eur Neuropsychopharmacol; 2005 Jan 28; 15(1):69-74. PubMed ID: 15572275
    [Abstract] [Full Text] [Related]

  • 32. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
    Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR.
    Psychiatry Res; 2019 Dec 28; 282():112602. PubMed ID: 31630042
    [Abstract] [Full Text] [Related]

  • 33. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
    Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C.
    J Clin Psychiatry; 2006 Jan 28; 67(1):15-22. PubMed ID: 16426083
    [Abstract] [Full Text] [Related]

  • 34. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.
    Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M.
    J Clin Psychiatry; 2005 Mar 28; 66(3):353-9. PubMed ID: 15766302
    [Abstract] [Full Text] [Related]

  • 35. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
    Naderi S, Faghih H, Aqamolaei A, Mortazavi SH, Mortezaei A, Sahebolzamani E, Rezaei F, Akhondzadeh S.
    Psychiatry Clin Neurosci; 2019 Apr 28; 73(4):169-174. PubMed ID: 30488617
    [Abstract] [Full Text] [Related]

  • 36. Citalopram for treatment-resistant obsessive-compulsive disorder.
    Pallanti S, Quercioli L, Paiva RS, Koran LM.
    Eur Psychiatry; 1999 Apr 28; 14(2):101-6. PubMed ID: 10572334
    [Abstract] [Full Text] [Related]

  • 37. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Aboujaoude E, Barry JJ, Gamel N.
    J Clin Psychopharmacol; 2009 Feb 28; 29(1):51-5. PubMed ID: 19142108
    [Abstract] [Full Text] [Related]

  • 38. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M, Bulut SD, Bozkurt A, Ozsahin A.
    Adv Ther; 2011 Apr 28; 28(4):341-8. PubMed ID: 21437763
    [Abstract] [Full Text] [Related]

  • 39. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.
    Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, Liebowitz M, Lydiard RB, McElroy S, Mendels J, O'Connor K.
    Int Clin Psychopharmacol; 1997 Nov 28; 12(6):309-16. PubMed ID: 9547132
    [Abstract] [Full Text] [Related]

  • 40. Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial.
    Mowla A, Dastgheib SA, Razeghian Jahromi L.
    Clin Drug Investig; 2016 Jul 28; 36(7):539-43. PubMed ID: 27071759
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.